MedPath

Nitrofurantoin

Generic Name
Nitrofurantoin
Brand Names
Furadantin, Macrobid, Macrodantin
Drug Type
Small Molecule
Chemical Formula
C8H6N4O5
CAS Number
67-20-9
Unique Ingredient Identifier
927AH8112L
Background

Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.

Nitrofurantoin was granted FDA approval on 6 February 1953.

Indication

Nitrofurantoin is indicated to treat acute uncomplicated urinary tract infections.

Associated Conditions
Acute Cystitis, Urinary Tract Infection
Clinical Trials
Related News

Antibiotic Prophylaxis for Clean Intermittent Catheterisation

Phase 4
Completed
Conditions
Urinary Tract Infections, Recurrent
Interventions
Other: No prophylaxis
First Posted Date
2014-05-22
Last Posted Date
2018-03-30
Lead Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Target Recruit Count
404
Registration Number
NCT02145338
Locations
🇬🇧

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract

Phase 3
Active, not recruiting
Conditions
Renal Hypodysplasia, Nonsyndromic, 1
Vesicoureteral Reflux
Chronic Kidney Disease
Interventions
Other: No prophylaxis
Drug: Amoxicillin-Potassium Clavulanate Combination
Drug: Trimethoprim/sulfamethoxazole
First Posted Date
2013-12-27
Last Posted Date
2023-09-28
Lead Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Target Recruit Count
292
Registration Number
NCT02021006
Locations
🇮🇹

Pediatric Nephrology Dialysis and Transplant Unit IRCCS Ca'Granda, Milan, Italy

Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women

Phase 4
Conditions
Urinary Tract Infections
Cystitis
Interventions
First Posted Date
2013-10-21
Last Posted Date
2017-05-02
Lead Sponsor
University Hospital, Geneva
Target Recruit Count
600
Registration Number
NCT01966653
Locations
🇮🇱

Tel Aviv University, Tel Aviv, Israel

🇵🇱

Lodz University Hospital, Lodz, Poland

🇨🇭

University Hospitals of Geneva, Geneva, Switzerland

A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department

Phase 4
Completed
Conditions
Uncomplicated Bacterial Cystitis
Interventions
First Posted Date
2012-12-13
Last Posted Date
2017-05-31
Lead Sponsor
University of Iowa
Target Recruit Count
35
Registration Number
NCT01749605
Locations
🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections

Not Applicable
Completed
Conditions
Pregnancy Complications
Interventions
Drug: Preventive antibiotic treatment- CEPHALEXIN
Drug: PREVENTIVE TREATMENT- CEFUROXIME
Drug: PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM
First Posted Date
2012-01-11
Last Posted Date
2020-05-19
Lead Sponsor
HaEmek Medical Center, Israel
Target Recruit Count
220
Registration Number
NCT01507974
Locations
🇮🇱

Dep of OG/GYN, Emek Medical Center, Afula, Israel

Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)

Phase 4
Completed
Conditions
Urinary Tract Infection
Interventions
Drug: Placebo
First Posted Date
2011-10-12
Last Posted Date
2017-02-13
Lead Sponsor
Duke University
Target Recruit Count
163
Registration Number
NCT01450800
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Efficacy and Safety of Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infections in Adults

Phase 4
Completed
Conditions
Urinary Tract Infection
Interventions
First Posted Date
2010-03-24
Last Posted Date
2010-03-24
Lead Sponsor
Mepha Ltd.
Target Recruit Count
37
Registration Number
NCT01092351
Locations
🇲🇽

Cif Biotec, Medica Sur, Mexico City, Mexico

Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg

First Posted Date
2009-11-23
Last Posted Date
2024-04-23
Lead Sponsor
Mylan Pharmaceuticals Inc
Target Recruit Count
80
Registration Number
NCT01018342
Locations
🇺🇸

Kendle International Inc., Morgantown, West Virginia, United States

Bioequivalence Study of Nitrofurantoin 100 mg Capsules Under Fed Conditions

Not Applicable
Completed
Conditions
Healthy
Interventions
First Posted Date
2008-10-23
Last Posted Date
2008-10-23
Lead Sponsor
Ranbaxy Laboratories Limited
Target Recruit Count
40
Registration Number
NCT00778583
Locations
🇮🇳

Ranbaxy Research Laboratories, Gurgaon, Haryana, India

Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence

Phase 4
Completed
Conditions
Stress Incontinence
Interventions
Other: Placebo
First Posted Date
2008-08-14
Last Posted Date
2016-10-11
Lead Sponsor
University of Missouri-Columbia
Target Recruit Count
161
Registration Number
NCT00734968
Locations
🇺🇸

Scott and White Hosptial, Texas A&M University, Temple, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy